Advisors Capital Management’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$404K Buy
1,043
+198
+23% +$73.4K ﹤0.01% 470
2026
Q1
$247K Sell
845
-61
-7% -$20K ﹤0.01% 512
2025
Q4
$318K Sell
906
-111
-11% -$37.5K ﹤0.01% 484
2025
Q3
$329K Sell
1,017
-314
-24% -$97.7K ﹤0.01% 464
2025
Q2
$518K Buy
1,331
+176
+15% +$70.8K 0.01% 369
2025
Q1
$503K Sell
1,155
-382
-25% -$153K 0.01% 360
2024
Q4
$567K Sell
1,537
-256
-14% -$107K 0.01% 358
2024
Q3
$933K Buy
1,793
+88
+5% +$47K 0.02% 299
2024
Q2
$924K Buy
1,705
+229
+16% +$121K 0.02% 298
2024
Q1
$766K Buy
1,476
+1
+0.1% +$497 0.01% 312
2023
Q4
$696K Buy
+1,475
New +$682K 0.01% 315
2023
Q3
Sell
-775
Closed -$344K 430
2023
Q2
$344K Sell
775
-66
-8% -$30.4K 0.01% 358
2023
Q1
$387K Buy
841
+20
+2% +$9.52K 0.01% 331
2022
Q4
$421K Sell
821
-13
-2% -$6.6K 0.01% 330
2022
Q3
$409K Sell
834
-221
-21% -$106K 0.01% 342
2022
Q2
$509K Sell
1,055
-18
-2% -$8.9K 0.02% 297
2022
Q1
$527K Buy
1,073
+272
+34% +$124K 0.01% 307
2021
Q4
$371K Sell
801
-49
-6% -$20.6K 0.01% 342
2021
Q3
$317K Sell
850
-1
-0.1% -$380 0.01% 343
2021
Q2
$325K Buy
851
+56
+7% +$21.4K 0.01% 322
2021
Q1
$285K Buy
795
+38
+5% +$12.2K 0.01% 320
2020
Q4
$243K Sell
757
-71
-9% -$21.8K 0.01% 313
2020
Q3
$223K Buy
828
+51
+7% +$13.7K 0.01% 283
2020
Q2
$204K Sell
777
-55,265
-99% -$14.7M 0.01% 284
2020
Q1
$12.7M Buy
56,042
+2,086
+4% +$568K 0.81% 47
2019
Q4
$16.3M Buy
53,956
+1,356
+3% +$373K 0.76% 46
2019
Q3
$12.6M Buy
52,600
+354
+0.7% +$97K 0.69% 53
2019
Q2
$14.7M Buy
52,246
+2,634
+5% +$720K 0.88% 41
2019
Q1
$14.3M Sell
49,612
-4,309
-8% -$1.25M 0.89% 44
2018
Q4
$14.2M Sell
53,921
-4,389
-8% -$1.21M 1.03% 30
2018
Q3
$16M Sell
58,310
-3,166
-5% -$822K 1.04% 29
2018
Q2
$14.6M Sell
61,476
-584
-0.9% -$135K 1.01% 34
2018
Q1
$13.6M Sell
62,060
-2,559
-4% -$601K 1.03% 34
2017
Q4
$14.5M Sell
64,619
-3,037
-4% -$647K 1.15% 29
2017
Q3
$12.8M Buy
67,656
+82
+0.1% +$15.6K 1.04% 31
2017
Q2
$12.7M Sell
67,574
-105
-0.2% -$18.9K 1.04% 33
2017
Q1
$11.2M Sell
67,679
-369
-0.5% -$58.7K 0.96% 35
2016
Q4
$9.78M Buy
68,048
+2,623
+4% +$351K 0.94% 37
2016
Q3
$8.2M Buy
65,425
+2,606
+4% +$336K 0.8% 45
2016
Q2
$8.25M Sell
62,819
-3,896
-6% -$533K 0.85% 42
2016
Q1
$9.27M Sell
66,715
-6,602
-9% -$882K 0.94% 40
2015
Q4
$10.2M Buy
73,317
+22,784
+45% +$3.14M 1.03% 39
2015
Q3
$7.08M Buy
50,533
+14,488
+40% +$2.18M 0.77% 48
2015
Q2
$5.92M Buy
36,045
+2,068
+6% +$330K 0.64% 59
2015
Q1
$5.25M Buy
33,977
+581
+2% +$82.7K 0.59% 62
2014
Q4
$4.2M Sell
33,396
-50
-0.1% -$6.18K 0.51% 71
2014
Q3
$4M Buy
33,446
+1,841
+6% +$211K 0.51% 75
2014
Q2
$3.4M Buy
31,605
+2,180
+7% +$225K 0.46% 83
2014
Q1
$2.93M Buy
29,425
+2,730
+10% +$247K 0.45% 81
2013
Q4
$2.47M Buy
26,695
+3,211
+14% +$285K 0.42% 87
2013
Q3
$1.96M Buy
23,484
+2,960
+14% +$254K 0.4% 88
2013
Q2
$1.68M Buy
+20,524
New +$1.54M 0.38% 87

Other funds holding ELV

Advisors Capital Management's ELV Position: Q2 2026 in Review

Advisors Capital Management increased its Elevance Health (ELV) stake by 23% in Q2 2026, buying an estimated $73.4K and bringing the position to 1,043 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Advisors Capital Management first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $16.3M in Q4 2019. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Advisors Capital Management held 1,043 shares of Elevance Health worth $404K as of Q2 2026.
  • Advisors Capital Management bought 198 Elevance Health shares in Q2 2026, an estimated $73.4K.
  • Elevance Health made up ﹤0.01% of Advisors Capital Management's portfolio in Q2 2026, its #470 holding.
  • Advisors Capital Management first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
  • Advisors Capital Management's Elevance Health position peaked at $16.3M in Q4 2019.
  • 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.